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Tomotherapy treatments. Median age of these patients was 60.6 yrs 
(21.6- 88.5). Median follow up was 15.7 mts (0.4- 58). They were 20 
cervical, 10 endometrial, 4 vaginal, 1 vulvar and 5 ovarian cancer. 
Four pts presented stage I, 9 stage II, 8 stage III, 2 stage IV,1 NA and 
16 relapsing tumors. Fourteen patients had a previous surgery. 
PET/CTsimulation was always performed to include pelvic or lombo- 
aortic N+ and tumor localizations in SIB. Fifteen patients were treated 
without SIB, with doses ranging from 45Gy/ 20 fr to 65.4 Gy/ 33 fr. 
Twenty five patients, who could not undergo BT or who had positive 
lymph nodes at FDG PET/CT, were treated with 45-50.4 Gy to 
pelvic/lombo-aortic lymph-nodes and a SIB on PET positive lymph-
nodes or central tumor. The median dose prescribed was 60 Gy( 45- 
66.25) in a median number of 28 fr (6- 33). Some of the cervical 
cancer patients also received concomitant chemotherapy. 
Results: RTOG acute toxicity was asf ollows: GE( diarrhea, nausea, 
vomiting) : G1= 9, G2= 14, G3= 1; GI(bleeding,tenesmus): G1= 1, G2= 
2; GU: G1= 7, G2= 6; hematologic (neutropenia): G1= 1,G2=1; G3= 1; 
dermatitis: G1= 3, G2=9, asthenia G1= 3. RTOG/EORTC late toxicity 
was: GE: G1= 3, G2= 1; GI: G3=1; GU: G1=2, G2=2; radiation 
dermatitis: G1=1.One patient presented vaginal sthenosis after 
exclusive HT treatment to 66,25Gy. Twenty CR, 9 PR, 2 SD and 2 PD 
were registered. Seven patients presented distant progressive disease 
with local CR (5)or PR (2) at the first evaluation. The 2 SD and 2 of PR 
presented local PD atthe next follow up. Thirteen patients have 
chosen to continue the follow up only with the gynecologist. Six 
deaths were registered among the patients who continued follow up, 
five in patients with PD, one in a patient with local CR but with brain 
metastases. 
Conclusions: The toxicity and local control results were good in this 
group of patients, demonstrating that, when necessary, brachytherapy 
could be replaced, and PET positive lymph nodes controlled, with the 
SIB technique. Disease progression with distant (lung,peritoneum) 
metastasis is indicative that a better systemic therapy should be 
developed.  
   
EP-1100   
Searching for prognostic factors of radiochemotherapy effects in 
advance cervical cancer patients.  
Z. Warenczak- Florczak1, K. Bratos1, H. Wlodarczyk1, E. Burchard1, B. 
Urbanski1, A. Roszak1 
1Great Poland Cancer Centre, Gynecological Oncology, Poznan, Poland  
 
Purpose/Objective: Cervical cancer is still on the five place of 
cancers in woman on the world. Radiotherapy, alongside with surgery 
and chemotherapy, is an important part of the therapeutic process in 
women suffering from these cancers. In the advance cases 
combination of radio and chemotherapy start to be the gold standard 
of treatment. The aim of this study was to assess the therapeutic 
effect according to five years survival and analysis of association 
between prognostic factors and results of the treatment. 
Materials and Methods: The study covered 151 patients with 
diagnosed FIGO stage IIB and IIIB cancer of the cervix treated on 2002 
to 2005 year. All patients received external-beam radiation therapy 
(EBRT) and brachytherapy (BRT) in combination with chemotherapy 
(CHT)– Cisplatin at 40mg/m² administered once a week over the 
radiotherapy period. The mean age of patients was 51 years old. 
91,6% got planoepitheliale carcinoma histopathology. The mean tumor 
size was 4,96cm, bigger in the group with IIIB cancer- 5,23cm. An 
average to point A dose in this group of patients was 87,1 Gy; 31,9Gy 
by the teleradiotherapy and 52,2Gy by the brachytherapy LDR or PDR. 
Chemotherapy was given in 1-7 curses, with mean dose of 4,7 curses, 
69,5% of patient got 5 and more courses. Meantime of the treatment 
was 38 days. The radiochemotherapy results were evaluated based on 
medical documentation and irradiation sheets. Subject to 
investigation was time of survival, present of absent of disease or 
metastasis and both early and late toxicity observed during a five year 
follow-up. 
Results: After five year observation we found that 88 patients (58,3%) 
was still alive and 63 patients (41,7%) died during this observation. 
Mean time to dead in group of 63 patient was 25,2 months after 
treatment. In 35 cases of death patients and in 13 cases with 5 years 
survival metastasis or recurrence was observed. Most important 
factors to five years survival was tumor volume (p<0,05) and 
associated with it stage of the disease. In the group with IIB stage 75% 
survived 5 years, in IIIB 53,8%. Rest of factor was important in 
comparing of IIB and IIIB stages, like dose of tele and brachytherapy, 
number of chemotherapy courses and prolong time of treatment. 
Conclusions: Radiochemotherapy became the gold standard in 
advanced cervical cancer women. During classification to that kind of 
treatment we must however remember that many factors became this 
treatment effectiveness or not. In some cases individualization of 
radio and chemotherapy combination can profiter with higher percent 
of five years survival.  
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Purpose/Objective: Hypofractionated treatment with intensity 
modulated radiotherapy (IMRT), arc therapy, stereotactic body 
radiotherapy (SBRT) and Cyberknife is a valid conservative alternative 
in exclusive or recurrent gynaecological cancer when brachytherapy is 
not feasible . 
Materials and Methods: In our 'Advanced Radiotherapy Center' the 
majority of patients (pts) affected by gynaecological cancer were 
treated with conventional or hypofractionated radiotherapy 
±brachytherapy boost. From June 2010 to October 2012 186 
gynaecological pts (90 exclusive cervical cancer) were treated. When 
brachytherapy is inadequate or not feasible, hypofractionated 
schedule with external beams is a very good solution (virtual 
brachytherapy). The introduction of new technologies such as IMRT, 
Rapid-arc therapy, SBRT, Cyberknife and the application of image 
guidance and adaptive planning techniques makes easier to spare 
critical organs at risk (OAR) in order to minimize late toxicity, that is 
a concern because of the closeness among OAR and target. In order to 
compare the different fractionation schedules, 2 Gy equivalent total 
doses (EQD2) were calculated using the linear quadratic model with 
α/β ratios of 3 Gy for late normal tissue effects and 10 Gy for the 
tumor. 
Results: All patients but five received Rapid arc radiotherapy with 
simultaneous integrated boost (SIB) :45-50.4 Gy (1.8 Gy/fraction (fr)) 
were prescribed to the T or T- bed, N0 pelvic and/or para-aortic 
lymph nodes and 55 Gy (2.2 Gy/fraction) to the positive lymph 
nodes.The dose for the hypofractionated boost schedule was 5 Gy/fr 
for 3 fr = 15 Gy , EQD2=18.8 Gy (PTV 65% ) isocenter EQD2=83 Gy or 5 
Gy/fr x 5 fr : 20 Gy EQD2 = 25 Gy.For the pts who received the 
hypofractionated treatment alone the doses for IMRT or SBRT was: 6 
Gy /fr x 5 fr= 30 Gy (isodose 95%)= EQD2=40 Gy, 5 Gy /fr x 5 fr = 25 Gy 
(isodose 95%) EQD2=30 Gy. 
Conclusions: The possibility to hypofractionate the treatment offers a 
new approach for a minimally invasive treatment in the management 
of cancer when current surgical approach and other conventional 
radiotherapy techniques are unsuitable. 
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Purpose/Objective: To assess the outcome and quality of life of 
patients of carcinoma cervix treated with multimodality therapy using 
the LENT SOMA scores. 
Materials and Methods: Patients:The study was prospective and 
patients who were treated in CMC, Ludhiana between 1st January 
1995to 31st December 2007 and coming for follow up were included in 
this study after ethical clearance. A total of 85 patients were accrued 
comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage 
III B and 1 stage IV A disease. Sixty six patients were treated with 
radiotherapy in which 45 patients received chemotherapy with 
radiotherapy and 19 had surgery prior to post-operative radiotherapy. 
The mean age was 47.81 years with a range of 25–68 years. 
Radiotherapy was given according to the Manchester school.  
Completion of LENT SOMA scale vagina sub-section (including sexual 
dysfunction) was done and Statistical analysis was done. 
Results:  
Completion of questionnaires: From a consecutive series of 92 
patients, 7 patients data were not adequate. Three patients were 
reported to have recurrence either local or metastatic. Initial data 
were obtained for 85 women. 
 Treatment data: Pre-radiotherapy LENT subjective scores for the 
vagina and sexual dysfunction scales were not obtained.  
There was a significant relationship between the average baseline 
scores and patient age (P =0:037) for the vagina scale score and also 
for sexual dysfunction (P =0:038). There was a significant relationship 
between the maximum vagina scores at baseline and age (P =0:039), 
but not for stage of disease (P = 0:077). For sexual dysfunction 
maximum scores there was no significant association with age (P 
